Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P3010
Description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company'sĀ development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | -0.24 | |||||
| Debt-to-Equity | -3.03 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.5 | |||||
| 3-Year FCF Growth Rate | 39.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.74 | |||||
| Quick Ratio | 0.74 | |||||
| Cash Ratio | 0.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | 0.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -425.8 | |||||
| ROA % | -98.58 | |||||
| ROIC % | -244.34 | |||||
| ROC (Joel Greenblatt) % | -955.11 | |||||
| ROCE % | -190.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -8.58 | |||||
| EV-to-EBITDA | -8.7 | |||||
| EV-to-FCF | -10.81 | |||||
| Earnings Yield (Greenblatt) % | -11.66 | |||||
| FCF Yield % | -9.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Corbus Pharmaceuticals Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -10.35 | ||
| Beta | -0.16 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 35.46 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 35.46 - 35.46 | ||
| Shares Outstanding (Mil) | 10.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corbus Pharmaceuticals Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(LTS:0SZI)'s stock price today?
The current price of LTS:0SZI is $35.46. The 52 week high of LTS:0SZI is $35.46 and 52 week low is $35.46.
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(LTS:0SZI)?
The next earnings date of Corbus Pharmaceuticals Holdings Inc(LTS:0SZI) is 2024-05-09 Est..
Does Corbus Pharmaceuticals Holdings Inc(LTS:0SZI) pay dividends? If so, how much?
Corbus Pharmaceuticals Holdings Inc(LTS:0SZI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers